Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


XenoPort's PD drug disappoints, failing next to Sinemet

This article was originally published in Scrip

Executive Summary

XenoPort said that preliminary top-line results from 28 evaluable patients in a Phase II trial of its investigational Parkinson’s agent XP21279 (sustained-release transported prodrug of levodopa) plus carbidopa did not met the primary endpoint and showed no difference from a standard drug. XenoPort has aimed to show that the co-formulated product, designed for sustained release, can reduce the fluctuations of levodopa in the bloodstream compared to the standard of care, Sinemet (immediate-release levodopa/carbidopa).


Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts